UnknownPhase 3NCT00003602

Combination Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia

Studying Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Riverside Haematology Group
Principal Investigator
Graham Jackson, MD
Newcastle-upon-Tyne Hospitals NHS Trust
Intervention
cytarabine(drug)
Enrollment
400 enrolled
Eligibility
55 years · All sexes
Timeline
1998

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00003602 on ClinicalTrials.gov

Other trials for Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent

Additional recruiting or active studies for the same condition.

See all trials for Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent

← Back to all trials